Heart failure & cardiomyopathies
Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy
Authors' conclusion
In the TTRACK study, almost one in five patients ≥50 years of age with hypertrophic cardiomyopathy had transthyretin amyloid cardiomyopathy.
Study context
- Population
- Patients aged ≥50 years with HCM (maximal end-diastolic LV wall thickness ≥15 mm) of unascertained aetiology, undergoing 99mTc bone scintigraphy75 (9.8%) scintigraphy plus SPECT
- Participants
- 766 patients
- Outcome
- Prevalence of transthyretin amyloid cardiomyopathy (grade 2 or 3 cardiac uptake, no plasma cell dyscrasia)
Methodological detailsmulticentre, non-interventional, epidemiologic, 20 hospitals and medical centres in 11 countries
- Multicentre
- Non-interventional
- Epidemiologic
- 20 hospitals and medical centres in 11 countries
Main finding
As reported in the abstract
Transthyretin amyloid cardiomyopathy
Grade 2 or 3 cardiac uptake on scintigraphy
208
27.2%
Diagnosed with transthyretin amyloid cardiomyopathy
144
18.8%
Observational data: associations, not effects.
Further findings
Characteristics of transthyretin amyloid cardiomyopathy
- Pathogenic testing and transthyretin (TTR) gene variant
- 11 (7.6%)
- NYHA class I
- 34 (23.8%)
- NYHA class II
- 74 (51.7%)
- NYHA class III/IV
- 35 (24.5%)
- Clinical and laboratory diagnostic characteristics
- ≥90%
Characteristics associated with transthyretin amyloid cardiomyopathy (multivariable analysis)
- Carpal tunnel syndrome, OR
- 54.3; P < 0.0001
- Male sex, OR
- 7.9; P < 0.0001
Original publication
Prevalence and Characteristics of Transthyretin Amyloid Cardiomyopathy in Hypertrophic Cardiomyopathy. ESC Heart Fail. Published 29 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →